- $20.99m
- -$35.56m
- $48.82m
- 58
- 99
- 37
- 70
Annual balance sheet for MEI Pharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 74.5 | 183 | 153 | 153 | 101 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.96 | 23.3 | 7.58 | 10 | 0.085 |
| Prepaid Expenses | |||||
| Total Current Assets | 82.2 | 209 | 165 | 167 | 108 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.204 | 1.08 | 9.28 | 10.7 | 13.3 |
| Net Intangible Assets | |||||
| Total Assets | 82.7 | 210 | 174 | 178 | 121 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 14.3 | 13.8 | 20.2 | 24.4 | 20.3 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 34.7 | 133 | 125 | 125 | 96.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 47.9 | 77.1 | 49.5 | 52.4 | 24.6 |
| Total Liabilities & Shareholders' Equity | 82.7 | 210 | 174 | 178 | 121 |
| Total Common Shares Outstanding |